Annual Cash & Cash Equivalents
$248.66 M
+$2.57 M+1.05%
31 December 2022
Summary:
NuVasive annual cash & cash equivalents is currently $248.66 million, with the most recent change of +$2.57 million (+1.05%) on 31 December 2022. During the last 3 years, it has risen by +$2.57 million (+1.05%).NUVA Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$80.72 M
-$100.48 M-55.45%
30 June 2023
Summary:
NuVasive quarterly cash and cash equivalents is currently $80.72 million, with the most recent change of -$100.48 million (-55.45%) on 30 June 2023.NUVA Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NUVA Cash And Cash Equivalents Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | - | - |
3 y3 years | +1.1% | -67.2% |
5 y5 years | +16.7% | -62.1% |
NUVA Cash And Cash Equivalents High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | ||||
5 y | 5 years | ||||
alltime | all time | -71.0% | -90.6% |
NuVasive Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
June 2023 | - | $80.72 M(-55.5%) |
Mar 2023 | - | $181.20 M(-27.1%) |
Dec 2022 | $248.66 M(+1.0%) | $248.66 M(+4.7%) |
Sept 2022 | - | $237.50 M(+5.1%) |
June 2022 | - | $225.99 M(+10.1%) |
Mar 2022 | - | $205.31 M(-16.6%) |
Dec 2021 | $246.09 M(-71.3%) | $246.09 M(+4.9%) |
Sept 2021 | - | $234.58 M(+14.9%) |
June 2021 | - | $204.14 M(-12.7%) |
Mar 2021 | - | $233.86 M(-72.7%) |
Dec 2020 | $856.87 M(+302.2%) | $856.87 M(+10.6%) |
Sept 2020 | - | $774.54 M(-2.8%) |
June 2020 | - | $796.77 M(+55.6%) |
Mar 2020 | - | $511.98 M(+140.3%) |
Dec 2019 | $213.03 M(+80.8%) | $213.03 M(+30.4%) |
Sept 2019 | - | $163.40 M(+27.3%) |
June 2019 | - | $128.38 M(+37.5%) |
Mar 2019 | - | $93.39 M(-20.7%) |
Dec 2018 | $117.84 M(+61.9%) | $117.84 M(+56.9%) |
Sept 2018 | - | $75.11 M(+7.2%) |
June 2018 | - | $70.08 M(-5.0%) |
Mar 2018 | - | $73.74 M(+1.3%) |
Dec 2017 | $72.80 M(-52.6%) | $72.80 M(+17.0%) |
Sept 2017 | - | $62.20 M(-52.5%) |
June 2017 | - | $130.93 M(-2.3%) |
Mar 2017 | - | $134.01 M(-12.8%) |
Dec 2016 | $153.64 M(-20.1%) | $153.64 M(-24.6%) |
Sept 2016 | - | $203.82 M(-22.5%) |
June 2016 | - | $263.08 M(-2.6%) |
Mar 2016 | - | $270.11 M(+40.4%) |
Dec 2015 | $192.34 M(+35.1%) | $192.34 M(+36.1%) |
Sept 2015 | - | $141.33 M(+79.7%) |
June 2015 | - | $78.64 M(-11.1%) |
Mar 2015 | - | $88.49 M(-37.8%) |
Dec 2014 | $142.39 M(+38.5%) | $142.39 M(+9.0%) |
Sept 2014 | - | $130.66 M(+22.7%) |
June 2014 | - | $106.46 M(-3.9%) |
Mar 2014 | - | $110.78 M(+7.7%) |
Dec 2013 | $102.83 M | $102.83 M(+2.2%) |
Sept 2013 | - | $100.62 M(+70.9%) |
Date | Annual | Quarterly |
---|---|---|
June 2013 | - | $58.88 M(-25.0%) |
Mar 2013 | - | $78.47 M(-36.4%) |
Dec 2012 | $123.30 M(-24.6%) | $123.30 M(+14.5%) |
Sept 2012 | - | $107.73 M(-11.1%) |
June 2012 | - | $121.16 M(-55.2%) |
Mar 2012 | - | $270.18 M(+65.3%) |
Dec 2011 | $163.49 M(+76.6%) | $163.49 M(-26.0%) |
Sept 2011 | - | $220.94 M(-56.3%) |
June 2011 | - | $505.08 M(+276.6%) |
Mar 2011 | - | $134.10 M(+44.8%) |
Dec 2010 | $92.60 M(+41.6%) | $92.60 M(+31.2%) |
Sept 2010 | - | $70.59 M(+4.6%) |
June 2010 | - | $67.51 M(-13.1%) |
Mar 2010 | - | $77.66 M(+18.7%) |
Dec 2009 | $65.41 M(-50.6%) | $65.41 M(-51.3%) |
Sept 2009 | - | $134.28 M(-1.5%) |
June 2009 | - | $136.33 M(-5.8%) |
Mar 2009 | - | $144.76 M(+9.4%) |
Dec 2008 | $132.32 M(+113.7%) | $132.32 M(+26.8%) |
Sept 2008 | - | $104.39 M(-23.4%) |
June 2008 | - | $136.22 M(-47.3%) |
Mar 2008 | - | $258.53 M(+317.6%) |
Dec 2007 | $61.91 M(+49.3%) | $61.91 M(+9.9%) |
Sept 2007 | - | $56.34 M(+27.4%) |
June 2007 | - | $44.22 M(+18.2%) |
Mar 2007 | - | $37.40 M(-9.8%) |
Dec 2006 | $41.48 M(+230.6%) | $41.48 M(-20.8%) |
Sept 2006 | - | $52.36 M(-48.7%) |
June 2006 | - | $102.06 M(-5.3%) |
Mar 2006 | - | $107.76 M(+759.0%) |
Dec 2005 | $12.54 M(+46.6%) | $12.54 M(+39.1%) |
Sept 2005 | - | $9.02 M(+74.3%) |
June 2005 | - | $5.17 M(-68.4%) |
Mar 2005 | - | $16.37 M(+91.3%) |
Dec 2004 | $8.56 M(+52.0%) | $8.56 M(-53.1%) |
Sept 2004 | - | $18.24 M(-37.1%) |
June 2004 | - | $28.99 M(+288.8%) |
Mar 2004 | - | $7.46 M |
Dec 2003 | $5.63 M(-18.5%) | - |
Dec 2002 | $6.91 M | - |
FAQ
- What is NuVasive annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for NuVasive?
- What is NuVasive quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for NuVasive?
What is NuVasive annual cash & cash equivalents?
The current annual cash & cash equivalents of NUVA is $248.66 M
What is the all time high annual cash & cash equivalents for NuVasive?
NuVasive all-time high annual cash & cash equivalents is $856.87 M
What is NuVasive quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of NUVA is $80.72 M
What is the all time high quarterly cash and cash equivalents for NuVasive?
NuVasive all-time high quarterly cash and cash equivalents is $856.87 M